Acetylcholine, an important mediator of gastric acid secretion (l, 2), has been shown by many laboratories to stimulate mucin secretion in the stomach (3-6). Coceani et al (7) cholinergic stimulation also significantly increased the release of prostaglandins (PGs), and that scopolamine completely suppressed the release of PGs induced by parasympathetic nerve stimulation. Seidel et al (8) have reported that intact vagal innervation is necessary for a mild irritant such as 30% ethanol to mediate the formation of mucosal PGs in the rat stomach. Moreover, Bickel and Kauffman (9) have demonstrated that PGE 2 increases gel mucus thickness in the stomach, and Seidler and coworkers (5, 10) have reported that both endogenous and exogenous prostaglandins stimulate glycoprotein secretion. However, the mechanism by which cholinergic agonists stimulate mucin secretion and their role in mucin synthesis, if any,
cholinergic stimulation also significantly increased the release of prostaglandins (PGs), and that scopolamine completely suppressed the release of PGs induced by parasympathetic nerve stimulation. Seidel et al (8) have reported that intact vagal innervation is necessary for a mild irritant such as 30% ethanol to mediate the formation of mucosal PGs in the rat stomach. Moreover, Bickel and Kauffman (9) have demonstrated that PGE 2 increases gel mucus thickness in the stomach, and Seidler and coworkers (5, 10) have reported that both endogenous and exogenous prostaglandins stimulate glycoprotein secretion. However, the mechanism by which cholinergic agonists stimulate mucin secretion and their role in mucin synthesis, if any, remains unclear. In the present study, we examined mucin synthesis induced by a cholinergic agonist in canine antral explants, focusing on the role of PGE2 as a possible intermediate messenger. Tissue Culture. The stomachs were excised immediately after conditioned mongrel dogs were anesthetized with 5 ml of 2% Surital. The muscular layer was dissected from the antrum, and the mucosal layer was cut into equal 2 x 2-ram pieces using razor blades mounted at 2-mm intervals on a cutting frame. Preliminary studies revealed that this method provided mucosal explants of uniform mass and geometry for culture. Ten tissue pieces were placed in each plastic culture well (diameter 35 mm) with 2 ml of medium consisting of DME/FI2 (1:1), L-glutamine, 15 mM HEPES, 7.5% fetal bovine serum (FBS), 7.5% heat-inactivated dog serum, and 0.05 mg/ml gentamicin (11) . We added 10 -5 M carbachol (Cb), 10 -5 M pirenzepine (PZ), 10 -5 M indomethacin (IND), 10 -5 M Cb + 10 -5 M PZ, 10 -5 M Cb + 10 -3 M IND + PGE z (10-8-10 -6 M) tO individual wells, and used phosphatebuffered saline (PBS) as a control additive. The doses of each agent were selected based upon prior experiments that indicated a maximal increase in mucin synthesis by isolated canine mucosal cells in response to 10 -5 M carbachol (JM Scheiman, ER Kraus, and CR Boland, unpublished data). The explants were incubated in the presence of 5 i~Ci/well D-[1,6--3H]/giucosamine at 37 ~ C under 5% CO2-95% Air for 24 hr. Wells were also maintained in the absence of [3H]glucosamine for the measurement of PGE2.
MATERIALS AND METHODS

Reagents
Assessment of Glycoprotein Synthesis. At the end of the period of incubation, media and tissue fragments were harvested together. After homogenization and sonication, they were centrifuged at 100,000g at 4~ for 1 hr to remove cellular debris. The supernatant was collected, and the glycoprotein was quantitated as follows: Two methods were used in an attempt to sensitively and specifically measure mucin. Newly synthesized mucin YOSHIMURA ET AL was metabolically labeled with [3H]glucosamine; one method relied upon the high molecular weight of mucin, and the other relied upon the ability to acid precipitate all proteins and glycoproteins. Our laboratory has used column chromatography extensively to purify gastric mucins; however, this does not remove noncovalently associated lipids that migrate with the mucins (11) . Acid precipitation permits the isolation of proteins and glycoproteins, and, moreover, permits the extraction of noncovalently bound lipids. Unfortunately, this technique may also measure nonmucin glycoproteins, which make up a small percentage of the glycoproteins produced by these cells. For method I, 1 ml of each supernatant was applied to a Sepharose-CL-4B column (1.5 x 50 cm) equilibrated in PBS and eluted at 20 ml/hr. The void volume was pooled, and 3H radioactivity was counted by liquid scintillation counting (12) . For method II, the supernatant was precipitated with 10% TCA and 1% PTA at 4 ~ C overnight. Then, the samples were centrifuged at 500g for 25 min, and the pellets were resuspended by sonication. Each pellet was washed three times with 10% TCA/I% PTA and twice with ether-ethanol (3:1). The pellets were dissolved in 2 ml of 0.6 M KOH and 3H radioactivity was measured (5) .
Measurement of Prostaglandin E 2. Fifty microliters of media was collected from each unlabeled well before (ie, immediately after placement in culture) and 24 hr after the administration of test agent and immediately frozen at -70 ~ C. PGE2 in media was quantitated by radioimmunoassay (RIA) in the University of Michigan Diabetes Center, Ligand Core Laboratory (13) . The PGE2 antibody was purchased commercially from Cayman Chemical Company (Ann Arbor, Michigan). Cross-reactivities with other prostaglandins are as follows: 15-keto-PGE 2-9.2%, and PGE1--5%; cross-reactivities were less than 0.2% for the following prostaglandins-PGA1, PGB1, PGB2, PGD 2, PGFI,,, 6-keto PGFl~ PGF2, . 13,14-dihydro-15-keto-PGF2~, and thromboxane B2 (manufacturer's specifications).
Statistical Analysis. The results are expressed as means --+ SE. N is the number of experiments performed on different dogs, although multiple measurements were carded out on each individual canine stomach. Statistical analysis was carded out with the Student's t test. P values of less than 0.05 were considered to be significant.
RESULTS
The results of each assay are expressed as a percentage of control wells in Figures 1, 3 , and 4, and as a percentage of Cb-treated wells in Figures 2 and 5.
Glyeoprotein Synthesis. Glycoprotein synthesis measured by method I was termed V0 (for void volume glycoprotein) and that by method II was termed Ppt (for acid-precipitated glycoprotein). The radioactivity in the 6 ml void volume peak (V0) under basal conditions of culture was 4335 ---605 cpm. Using the Ppt method in which the total glycoprotein faction was measured, 21,944 --+ 1,345 PGE 2 MEDIATES GLYCOPROTEIN SYNTHESIS manner, PZ also decreased the effect of Cb on glycoprotein synthesis to 73 -+ 8% (P < 0.01) as V 0 and to 78 _ 5% (P < 0.001) as Ppt.
As shown in Figure 3 lease to 5 ---3% of control (P < 0.001). PZ, 10 -5 M, failed to induce a significant change in PGE2 release.
As shown in Figure 5 , the addition of 10 -5 MIND suppressed the effect of 10 -5 M Cb on PGE z release to 1 ---1% (P < 0.001) of Cb-treated wells. PZ, 10 -5 M, also significantly inhibited the PGE2 release stimulated by Cb to 41 _+ 10% (P < 0.001) of that observed in Cb-treated wells.
DISCUSSION
The stimulant effect of the cholinergic agents on mucin synthesis or secretion has been reported from several laboratories. Gerard et al (4) have used histochemistry and incorporation of 35S into gastric epithelium to show that urecholine increased the apparent synthesis and secretion of mucus by fundic crypt cells and antral pyloric glands in vivo. Vagne and Perret (6) have demonstrated that the secretion of fucose-and galactose-containing gastric juice glycoconjugates was stimulated by carbachol. In the present study, [3H]glucosamine incorporation into antral tissues and new glycoprotein synthesis were significantly stimulated by the addition of carbachol to cultured explants, which is similar to the findings of Seidler and Sewing on glycoprotein secretion (5) . The dose of carbachol used to stimulate mucin synthesis (10 -5 M) may be pharmacological rather than physiological. However, it is very difficult to know what constitutes a physiological concentration of a neurocrine or paracrine substance, since unexpectedly high concentrations may be achieved at the target cell membranes. We have shown maximal stimulation of mucin synthesis by cultured canine gastric mucous 1048 YOSHIMURA ET AL cells by carbachol 10 -6 M to 10 -5 M, which is inhibitable by 10 -4 M atropine (unpublished data, manuscript submitted).
Various results have been reported for the effects of indomethacin on gastric mucous cell function. Some authors have reported that indomethacin decreased apparent gastric mucus secretion and the amount of carbohydrate in secreted "mucosubstances" (10, 14) and that it reduced the viability of mucosal cells (15) . In contrast, others have reported that the mucus content of antral mucosa showed no change during indomethacin therapy (16) and that indomethacin did not affect the viability of isolated gastric cells (17) . Our present study has shown that indomethacin significantly decreased glycoprotein synthesis, and the effect was reversed by exogenous PGE2 replacement. These discrepancies might be due to differences in experimental conditions but appear to reflect that the influence of indomethacin on mucous cells is not direct.
Prostaglandins (PGs) produced by the stomach have been shown to stimulate all recognized mucosal defense factors, including gastric and duodenal bicarbonate secretion, the production and release of mucus, surfactant lipid production and release with mucin (11), and they may have trophic effects on the gastric mucosa (18) . It has been reported that both endogenous and exogenous PGE 2 stimulated glycoprotein secretion (5, 10) and that PGE 2 caused a significant increase in mucous gel thickness (9, 19) . Offerhaus et al (20) have found that the increase in mucosal thickness after treatment with PGE2 did not seem to be caused by enhanced proliferative activity, but rather by retarded senescence, especially of the foveolar cell layer. It has been shown that PGE2 had a direct cellular "cytoprotective" action on gastric mucosal cells (15, 17) . It has been recently reported that gastric mucosa had specific receptors for PGE 2 and that receptor binding was an important initial step in PGE2-mediated cellular responses in the stomach (21).
Wollin et al (22) have reported that the adenylate cyclase activity was stimulated by both PGs and histamine in fundic mucosa, but only by PGs in antral mucosa, and that histamine and PGs stimulated two different adenylate cyclase systems. Soil, Wollin, and their colleagues (23, 24) have shown that PGE 2 stimulated the production of cyclic AMP by nonparietal cells. Heim et al (25) have recently reported that PGE 2 stimulated glycoprotein synthesis by pig gastric mucous cells. Our present study has shown that PGE2 significantly increased the PGE2 MEDIATES GLYCOPROTEIN SYNTHESIS glycoprotein synthesis suppressed by 10 -5 M indomethacin at a dose of 10 -6 M and 10 -7 M. However, exogenous PGE2 restored glycoprotein synthesis to a level slightly less than measured in control tissues. This might indicate that other PGs coordinately regulate glycoprotein synthesis or that indomethacin reduces the viability of mucous cells.
The present work demonstrates that the glycoprotein synthesis stimulated by carbachol was significantly reduced by both indomethacin and pirenzepine. This indicates that both PGs and muscarinic receptors participate in the stimulus-response mechanism of Cb. However, as we and other authors (26, 27) have shown, the M1 antagonist pirenzepine alone does not suppress glycoprotein synthesis. Nakamura et al (28, 29) have used [3H]pirenzepine and autoradiography to show that pirenzepine-binding sites are localized predominantly on parietal cells, chief cells, and capillary endothelium and that surface mucous and mucous neck cells had fewer pirenzepine binding sites. They have also suggested that parietal and chief cells possessed low-affinity Ml-muscarinic receptors, while the perivascular plexuses have highaffinity receptors. On the other hand, Lundell (30) has shown that acetylcholine stimulated histamine formation through muscarinic receptors on mast cells in a dose-dependent manner. Soil (2) has demonstrated that parietal cells account for most of the increase in oxygen uptake produced by exposure to gastric secretagogues in fundic isolated cell fractions. Thus, it is not likely that mucous and mucous neck cells have the same muscarinic receptors as parietal cells (1) . Pirenzepine at a dose of 10 -5 M may have a nonspecific muscarinic effect (ie, may not be M1 selective), so the precise definition of the receptor subtype remains to be proven.
It has been shown that cholinergic nerve stimulation and carbachol stimulate the release of PGE2 in the rat stomach (7) and that vagotomy prevents adaptive cytoprotection to the gastric mucosal injury induced by ethanol (8). Postius et al (31) have suggested that more PGE2 is produced by parietal than by mucosal or chief cells; moreover, Arakawa et al (17) have shown that surface epithelial cells predominantly produce 6-keto-prostaglandin FI~ and thromboxane B2, rather than PGE 2. In the present work, carbachol increased PGE2 release to a value more than twice the control value and significantly stimulated glycoprotein synthesis. The stimulation of PGE 2 release by carbachol was suppressed almost completely by the addition of indomethacin and was reduced to less than half by the addition of pirenzepine. This indicates the obligatory role of muscarinic receptors as an intermediate PGEE-releasing cell and suggests the participation of an additional cellular species in the regulation of mucus production in the intact stomach.
Seidler and Sewing (5) have demonstrated that cholinergic stimulation of mucus secretion is accompanied by an increase in intracellular Ca 2+, but that forskolin and PGE2 stimulate mucus secretion by independent mechanisms. In light of this, it may be suggested that there are at least two mechanisms by which mucin synthesis is induced by acetylcholine in the stomach. One requires PGE2-releasing cells that have muscarinic receptors, which could include capillary endothelial cells or mast cells. In fact, Chen et al (32) have demonstrated that macrophages and capillary endothelial cells are the major producers of PGE2 in the canine fundus. PGE 2 may activate adenylate cyclase and stimulate cAMP production in mucous cells through their specific receptors, stimulating mucin synthesis. In addition, nonspecific, low-affinity muscarinic receptors on mucus cells may function through a second mechanism to increase intracellular calcium and independently stimulate mucin synthesis and the secretion of mucus. The role of multiple agonists utilizing independent second messengers has been well demonstrated in the regulation of acid secretion by parietal cells (2, 23) . Although PGs inhibit secretory function in parietal cells through an interaction with the G(i) subunit of the transmembrane signal transduction mechanism (33), the intracellular mechanism of mucous cell response to PGs is not well understood.
In summary, we have demonstrated that the stimulation of glycoprotein synthesis by a cholinergic agonist may be inhibited by either a muscarinic antagonist (possibly MI) or by inhibiting PG production. This suggests that PGs serve as obligatory intermediate messengers in the mediation of cholinergic stimulation of mucous cell function. The intracellular events that mediate the post-PG response remain to be elucidated.
